Biography
Jeremy has extensive management experience in the life science industry. He specializes in commercial operations, technology development and transfer, manufacturing design, start-up, and analytical validation of laboratory-developed tests (LDTs). Jeremy was a key member of the Agencourt Personal Genomics team. Jeremy led the development and validation of all of Selah’s molecular assays and led the commercialization and application efforts for next generation sequencing at Life Technologies. While at Agencourt Personal Genomics, Jeremy was a co-developer of the SOLiD next-generation sequencing technology, where he co-authored several patents related to next-generation sequencing. Before entering the industry, Jeremy completed his postdoctoral work at the Dept. of Genetics & Complex Diseases at the Harvard School of Public Health. Jeremy earned his master’s degree in Toxicology from the University of Minnesota and his doctorate from Harvard University.

Talk
Leverage the Utility of Pharmacogenomics for Perioperative Treatments
Postoperative pain control remains a challenge for providers without a routine way to select personalized medication. Postop outcomes can show great improvement with pharmacogenetics analysis of multiple gene variants. Learn more about the Prospective Outcomes and Molecular Implementation Support Registry (PROMISRx) Study to better explain interpatient variability in response to perioperative treatment.

Pharmacogenomics (PGx) Showcase:
Precision Genetics